SCHEMBL3146530

SCHEMBL3146530

CC(C)C1CN(c2nccs2)CCN1C(=O)C#Cc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.41
SLC6A7 Q99884 1/20 0.41
AR P10275 1/20 0.39
HRH3 Q9Y5N1 1/20 0.38
SCD O00767 1/20 0.38
GRM5 P41594 5/20 0.38
GRM1 Q13255 1/20 0.35
ALDH1A1 P00352 2/20 0.34
DRD2 P14416 1/20 0.34
DRD4 P21917 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
KDM4E B2RXH2 1/20 0.34
PPARG P37231 1/20 0.34
NCOA2 Q15596 1/20 0.34
NCOA1 Q15788 1/20 0.34
VCP P55072 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3158565 0.87 SLC6A7 (0.43) HSD17B10SLC6A7ARSCDGRM5
SCHEMBL3148092 0.87 SLC6A7 (0.43) HSD17B10SLC6A7ARSCDGRM5
SCHEMBL3150861 0.87 SLC6A7 (0.43) HSD17B10SLC6A7ARSCDGRM5
Hydrochloric Acid SCHEMBL3152043 0.86 SLC6A7 (0.43) HSD17B10SLC6A7ARSCDGRM5
SCHEMBL3147235 0.85 HSD17B10 (0.42) HSD17B10SLC6A7ARSCDGRM5
SCHEMBL3151640 0.85 SLC6A7 (0.42) HSD17B10SLC6A7ARSCDGRM5
SCHEMBL3147934 0.84 HSD17B10 (0.43) HSD17B10SLC6A7ARSCDGRM5
SCHEMBL3144822 0.78 SLC6A7 (0.58) HSD17B10SLC6A7ARHRH3SCD
SCHEMBL5180013 0.78 PKM (0.43) HSD17B10SLC6A7HRH3SCDALDH1A1
SCHEMBL3146527 0.78 ALDH1A1 (0.39) HSD17B10SLC6A7HRH3SCDGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765816-B1 SUBSTITUTED 1-PROPIOLYLPIPERAZINES HAVING AN AFFINITY FOR THE MGLUR5 RECEPTOR IN ORDER TO TREAT PAINFUL CONDITIONS GRUENENTHAL GMBH (DE) 2010-03-10 EP claimed
US-7300939-B2 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-11-27 US claimed
US-20070112011-A1 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
EP-1765816-B1 SUBSTITUTED 1-PROPIOLYLPIPERAZINES HAVING AN AFFINITY FOR THE MGLUR5 RECEPTOR IN ORDER TO TREAT PAINFUL CONDITIONS GRUENENTHAL GMBH (DE) 2010-03-10 EP disclosed
US-7300939-B2 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-11-27 US disclosed
US-20070112011-A1 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112011-A1 Substituted 1-propiolylpiperazine compounds, their preparation and use GRM5, GRIK5, GRM1 HSD17B10 2925/4885SLC6A7 959/4885AR 2950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.